We are live on ! Find out more
XLO icon

Xilio Therapeutics
XLO

41 hedge funds and large institutions have $133M invested in Xilio Therapeutics in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 13 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.2% less ownership

Funds ownership: 5.09% → 4.88% (-0.2%)

2% less funds holding

Funds holding: 42 → 41 (-1)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

38% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 13

56% less capital invested

Capital invested by funds: $303M → $133M (-$170M)

Holders
41
Holders Change
-1
Holders Change %
-2.38%
% of All Funds
0.65%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
3
Increased
8
Reduced
13
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
State Street
State Street
Massachusetts
+$392K
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$231K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$85K
4
Bank of New York Mellon
Bank of New York Mellon
New York
+$76.7K
5
TRCT
Tower Research Capital (TRC)
New York
+$37.7K

Top Sellers

1
DM
Deerfield Management
New York
-$852K
2
CCM
CAAS Capital Management
New York
-$592K
3
MIM
Monashee Investment Management
Massachusetts
-$578K
4
GCM
Ghisallo Capital Management
Massachusetts
-$480K
5
DKCM
Davidson Kempner Capital Management
New York
-$458K
Name Holding Trade Value Shares
Change 		Change in
Stake
TRCT
26
Tower Research Capital (TRC)
New York
$30K +$37.7K +238 +345%
Deutsche Bank
27
Deutsche Bank
Germany
$28K -$5.38K -34 -11%
AIG
28
American International Group
New York
$27K -$1.74K -11 -4%
California State Teachers Retirement System (CalSTRS)
29
California State Teachers Retirement System (CalSTRS)
California
$23K -$9.81K -62 -21%
Bank of America
30
Bank of America
North Carolina
$19K -$24.4K -154 -45%
Morgan Stanley
31
Morgan Stanley
New York
$14K +$12K +76 +103%
Wells Fargo
32
Wells Fargo
California
$12K -$31.6K -200 -63%
SO
33
STRS Ohio
Ohio
$12K – – –
AB
34
Amalgamated Bank
New York
$8K +$12.2K +77 New
AF
35
Amalgamated Financial
New York
$8K +$12.2K +77 New
Barclays
36
Barclays
United Kingdom
$8K +$14.1K +89 New
UBS Group
37
UBS Group
Switzerland
$7K -$34K -215 -76%
Legal & General Group
38
Legal & General Group
United Kingdom
$5K – – –
AIP
39
Ameritas Investment Partners
Nebraska
$4K – – –
Royal Bank of Canada
40
Royal Bank of Canada
Ontario, Canada
$3K -$12.5K -79 -70%
Citigroup
41
Citigroup
New York
$2K -$21.2K -134 -85%
CCM
42
CAAS Capital Management
New York
– -$592K -2,644 Closed
GCM
43
Ghisallo Capital Management
Massachusetts
– -$480K -2,143 Closed
DKCM
44
Davidson Kempner Capital Management
New York
– -$458K -2,071 Closed
Marshall Wace
45
Marshall Wace
United Kingdom
– -$324K -1,442 Closed
1
2

XLO Hedge Fund Activity: Q1 2022 in Review

41 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Xilio Therapeutics (XLO) for Q1 2022, worth a combined $133M — down 56% from $303M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of XLO and 3 opened new positions — a net loss of 1 holder — while 13 trimmed existing stakes and 8 added.

The largest buyer was State Street, adding an estimated $392K. The largest seller was Deerfield Management, cutting an estimated $852K.

  • 41 institutional investors held Xilio Therapeutics (XLO) as of Q1 2022, down from 42 in Q4 2021.
  • Funds reported $133M of Xilio Therapeutics stock for Q1 2022, down 56% quarter-over-quarter.
  • 3 funds opened new Xilio Therapeutics positions in Q1 2022 and 4 closed out, a net change of -1 holder.
  • The largest Xilio Therapeutics buyer in Q1 2022 was State Street, an estimated $392K added.
  • The largest Xilio Therapeutics seller in Q1 2022 was Deerfield Management, an estimated $852K sold.

Based on aggregated 13F filings for Q1 2022.